Gilead steps into breach left by AbbVie as Galapagos' partner
Gilead Sciences has earmarked $2bn to take a stake in Belgium's Galapagos and buy into its filgotinib drug candidate for rheumatoid arthritis.
Copyright 2016 Green Nature. All rights reserved